Another 4-biomarker panel of KRAS, methylated NDRG4, SDC2, and TFPI2 (along with β-actin reference gene), displayed a higher performance when compared to other biomarker combinations, with CRC sensitivities and specificities of 90.0% (45/50) and 94.0% (47/50). The gene discussed is TFPI2; the disease is colorectal carcinoma.